Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YPEG-rhEPO in Anemia of Chronic Kidney Disease
NCT04885647Phase 2Completed
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of YPEG-rhEPO in anemia of chronic kidney disease (CKD-A), sponsored by Xiamen Tebao Biological Engineering Co., Ltd.. Started Mar 2021; status: completed.
02
Drugs
YPEG-rhEPO
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT04885647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04885647.